Next Generation Antisense Oligonucleotide Therapeutics for Oncology, CNS and Beyond

About us

Secarna Pharmaceuticals is the leading independent European antisense drug discovery company with multiple best-in-class antisense therapies in various stages of pre-clinical development addressing high unmet medical needs across several therapeutic areas. Founded in 2015, we are proud to have established our discovery and development unit with more than 2,000 square feet of lab and office space at the IZB Martinsried – one of Europe's most vibrant biotechnology clusters. 

Secarna is well established with a solid financial positioning and an experienced management team with a long and successful track record in drug development, corporate development and commercialization.

Our unique next-generation ASO platform, LNAplus™

Our state-of-the-art independent 3rd generation antisense oligonucleotide (ASO) platform, LNAplus™, encompasses all aspects of drug discovery and pre-clinical development and is proven to be fast, reliable, flexible and efficient. The platform combines the powerful proprietary Oligofyer™ bioinformatics and LNA Vit(r)ox™ screening system for best-in-class screening and target-specific functional assays. A key advantage of the LNAplus™ platform is rapid development candidate generation with IND enabling phase entry possible after only 24 weeks.

LNAplus™ as well as our ASOs identified by this platform have been validated by academic and industry partnerships with almost 20 high impact programs generated in the past years.

Our Mission

We aim to leverage our proprietary ASO discovery platform, LNAplus™, to bring novel, highly specific, safe and efficacious ASO therapies addressing a variety of targets deemed undruggable by current approaches to patients in need.

Latest News


19th Annual Meeting of the Oligonucleotide Therapeutics Society

Barcelona, Spain

October 22-25, 2023